Table 9.
Ongoing clinical trials on novel therapies.
| Trial | ALL subtype | Age | Phase | Overview |
|---|---|---|---|---|
| NCT03808610 | Relapse/refractory T and B-ALL | ≥18 years | Phase I/II | Combination of low-intensity chemotherapy and venetoclax in patients with relapsed/refractory ALL |
| NCT03504644 | Relapse/refractory T and B-ALL | ≥18 years | Phase IB/II | Combination of venetoclax and liposomal vincristine in Patients with Relapsed or Refractory ALL |
| NCT03808610 | Relapse/refractory T and B-ALL | ≥18 years | Phase I/II | Combination of low-intensity chemotherapy and venetoclax (ABT-199) in patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) |
| NCT04752163 | Relapse/refractory AML, ALL, CMML and MDS | ≥18 years | Open-Label Phase 1/2 | Single treatment of DS-1594b or combination with azacytidine and venetoclax or Mini-HCVD for the Treatment of AML and ALL |
| NCT03236857 | Various relapse/refractory malignancies, e.g., AML, ALL, neuroblastoma | Pediatric and young adults up to 25 years | Phase 1 | Study of safety and pharmacokinetics of venetoclax in pediatric and young adult patients with relapsed or refractory malignancies |
| NCT03117751 | Newly diagnosed T and B-ALL | 1–18 years | RCT | Add ruxolitinib for JAK-STAT hyperactivated ALL in combination with conventional chemotherapy |
| NCT03384654 | Relapse/refractory T and B-ALL | 1–30 years | Open-label, phase 2 | Investigation of efficacy and safety of daratumumab in pediatric and young adult with relapsed/refractory ALL |
| NCT03860844 | Relapse/refractory AML, T and B-ALL | 28 days to 17 years | Open-label, single-arm trial | Evaluation of antitumor activity, safety, and pharmacokinetics of isatuximab used in combination with chemotherapy in pediatric patients with relapsed/refractory ALL or AML |
| NCT03386513 | CD123-positive relapse/refractory hematological malignancies, including AML and ALL | ≥18 years | Phase I/II | Determine the maximum tolerated dose, evaluate safety, tolerability, pharmacokinetics, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease. |
| NCT04681105 | CD123-positive relapse/refractory hematological malignancies, including ALL and blastic plasmacytoid dendritic cell neoplasm | ≥12 years | Phase 1 | Determine the best dose and assess side effect of flotetuzumab in treating relapse/refractory CD123-positive malignancies |
| NCT03081910 | Relapse CD5-positive T-ALL and mature T-cell lymphoma | Pediatric to adults up to 75 years | Phase 1 | Phase 1 therapy with manufactured CAR-T cell for treatment of T-cell malignancies expressing CD5 antigen |
| NCT03690011 | Relapse CD7-positive T-ALL and mature T-cell lymphoma | Pediatric to adult up to 75 years | Phase 1 | Phase 1 Therapy with manufactured CAR-T cell for treatment of T-cell malignancies expressing CD7 antigen |
| NCT04004637 | Relapsed CD7-positive T-ALL/T lymphoblastic lymphoma, NK/T-cell lymphoma (T-LBL) | 7–70 years | Phase 1 | Investigate the safety and efficacy of CD7 CAR-T cells for patients with relapse/refractory CD7+ T-ALL/T-LBL, NK/T cell lymphoma and determine the pharmacokinetics of CD7 CAR-T cells in patients. |
| NCT04860817 | Relapse/refractory T-ALL/T-LBL | 2–25 years | Early Phase 1 | Investigate the safety and efficacy of CD7 CAR-T cell in treating relapse/refractory T-ALL/T-LBL |
| NCT04620655 | Relapse/refractory T-ALL/T-LBL | 3–70 years | Early phase 1 | Determine the dose-limiting toxicity of universal CD7 CAR-T cell in treating relapse/refractory T-ALL/T-LBL |